"I can attest with certainty that patients who struggle to make their copays while managing chronic, debilitating and life-threatening diseases require consistency in who is managing their disease condition and where," said Davenport-Ennis. "Reductions in Medicare reimbursement to physicians over the past several years have made it very difficult to maintain their practices in the critical community-based setting, where most patients receive their care. This cannot happen to our cancer delivery system."Health officials throughout the cancer community attribute this growing trend to both the effects of the sequester and reduced reimbursement for Medicare Part B drugs. Effective April 1, the federal sequester reduced reimbursement for Medicare Part B cancer therapies from the current Medicare payment rate of the "average sales price" (ASP) plus 6 percent to just ASP plus 4.3 percent, resulting in severe financial losses for practices that treat cancer patients in the community. Even before this change, community-based cancer clinics maintained that drug reimbursement rates failed to adequately pay for the acquisition and related costs (such as storage, inventory, waste disposal, pharmacy and admixture facilities and staff) of life-sustaining cancer drugs.
Nation's Leading Patient Advocate Organization Testifies Before Congressional Subcommittee On Access Barriers For Medicare Beneficiaries With Cancer
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.